References
- Aymard G, Warot D, Démolis P, et al. (2003). Comparative pharmacokinetics and pharmacodynamics of intravenous and oral nefopam in healthy volunteers. Pharmacol Toxicol 92:279–86
- Bolt AG, Graham G, Wilson P. (1974). Stereoselective demethylation of the enantiomers of nefopam, an experimental antidepressant and skeletal muscle relaxant. Xenobiotica 4:355–63
- Chawla J, Le Guern ME, Alquier C, et al. (2003). Effect of route of administration on the pharmacokinetic behavior of enantiomers of nefopam and desmethylnefopam. Ther Drug Monit 25:203–10
- Dell'Osso B, Buoli M, Baldwin DS, Altamura AC. (2010). Serotonin norepinephrine reuptake inhibitors (SNRIs) in anxiety disorders: a comprehensive review of their clinical efficacy. Hum Psychopharmacol 25:17–29
- Girard P, Coppé MC, Verniers D, et al. (2006). Role of catecholamines and serotonin receptor subtypes in nefopam-induced antinociception. Pharmacol Res 54:195–202
- Girard P, Pansart Y, Coppe MC, Gillardin JM. (2001). Nefopam reduces thermal hypersensitivity in acute and postoperative pain models in the rat. Pharmacol Res 44:541–5
- Gray AM, Nevinson MJ, Sewell RD. (1999). The involvement of opioidergic and noradrenergic mechanisms in nefopam antinociception. Eur J Pharmacol 365:149–57
- Gregori-Puigjané E, Setola V, Hert J, et al. (2012). Identifying mechanism-of-action targets for drugs and probes. Proc Natl Acad Sci USA 109:11178–83
- Heel RC, Brogden RN, Pakes GE, et al. (1980). Nefopam: a review of its pharmacological properties and therapeutic efficacy. Drugs 19:249–67
- Hunskaar S, Fasmer OB, Broch OJ, Hole K. (1987). Involvement of central serotonergic pathways in nefopam-induced antinociception. Eur J Pharmacol 138:77–82
- ICRP. (2008). Radiation dose to patients from radiopharmaceuticals – Addendum 3 to ICRP Publication 53. ICRP Publication 106. Ann ICRP 38 (1-2)
- Kirchherr HJ, Christ W. (1984). Nefopam and N-desmethyl-nefopam: Activity in the hot plate and writhing test. Naunyn Schmiedebergs Arch Pharmacol 325:R72
- Lee YC, Chen PP. (2010). A review of SSRIs and SNRIs in neuropathic pain. Expert Opin Pharmacother 11:2813–25
- Leurs R, Donnell D, Timmerman H, Bast A. (1987). Cytochrome P450 metabolic intermediate complex of nefopam. J Pharm Pharmacol 39:835–7
- Leurs R, Donnell D, Timmerman H, Bast A. (1989). Interaction of nefopam and orphenadrine with the cytochrome P-450 and the glutathione system in rat liver. J Pharm Pharmacol 41:388–93
- Mather GG, Labroo R, Le Guern ME, et al. (2000). Nefopam enantiomers: preclinical pharmacology/toxicology and pharmacokinetic characteristics in healthy subjects after intravenous administration. Chirality 12:153–9
- Novelli A, Diaz-Trelles R, Groppetti A, Fernandez-Sanchez MT. (2005). Nefopam inhibits calcium influx, cGMP formation, and NMDA receptor-dependent neurotoxicity following activation of voltage sensitive calcium channels. Amino Acids 28:183–91
- Novelli A, Groppetti A, Rossoni G, et al. (2007). Nefopam is more potent than carbamazepine for neuroprotection against veratridine in vitro and has anticonvulsant properties against both electrical and chemical stimulation. Amino Acids 32:323–32
- Poon R, Hong H, Wei X, et al. (2012). A high throughput screen identifies Nefopam as targeting cell proliferation in β-catenin driven neoplastic and reactive fibroproliferative disorders. PLoS One 7:e37940
- Taylor D, Lenox-Smith A, Bradley A. (2013). A review of the suitability of duloxetine and venlafaxine for use in patients with depression in primary care with a focus on cardiovascular safety, suicide and mortality due to antidepressant overdose. Ther Adv Psychopharmacol 3:151–61
- Thase ME. (2008). Are SNRIs more effective than SSRIs? A review of the current state of the controversy. Psychopharmacol Bull 41:58–85
- Verleye M, André N, Heulard I, Gillardin JM. (2004). Nefopam blocks voltage-sensitive sodium channels and modulates glutamatergic transmission in rodents. Brain Res 1013:249–55